Sarepta Therapeutics Inc
SRPT24.450USD
+0.440+1.83%
Close 11/03, 16:00（ET）Quotes delayed by 15 min
2.39BMarket Cap
LossP/E TTM
More Details of Sarepta Therapeutics Inc Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
Sarepta Therapeutics Inc Info
Ticker SymbolSRPT
Company nameSarepta Therapeutics Inc
IPO dateJun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Number of employees1372
Security typeOrdinary Share
Fiscal year-endJun 04
Address215 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code02142
Phone16172744000
Websitehttps://www.sarepta.com/
Ticker SymbolSRPT
IPO dateJun 04, 1997
CEOMr. Douglas S. (Doug) Ingram, Esq., J.D.
Company Executives of Sarepta Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Ms. Cristin L. Rothfuss
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
--
--
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
201.48K
+249.76%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
189.46K
+315.61%
Mr. Ryan Wong
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
136.20K
+686.03%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
By BusinessUSD
Name
Revenue
Proportion
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
By RegionUSD
Name
Revenue
Proportion
United States
484.77M
94.48%
Rest of World
28.35M
5.52%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
ELEVIDYS
281.85M
54.93%
PMO Products
231.27M
45.07%
collaboration and other
97.97M
19.09%
Shareholding Stats
Updated: Sat, Nov 1
Updated: Sat, Nov 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Investment Management (US)
4.49%
Two Sigma Investments, LP
3.96%
Other
67.15%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.17%
BlackRock Institutional Trust Company, N.A.
9.40%
D. E. Shaw & Co., L.P.
4.83%
State Street Investment Management (US)
4.49%
Two Sigma Investments, LP
3.96%
Other
67.15%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.26%
Investment Advisor/Hedge Fund
20.40%
Hedge Fund
20.05%
Research Firm
5.54%
Individual Investor
4.67%
Bank and Trust
1.24%
Pension Fund
1.13%
Sovereign Wealth Fund
0.90%
Insurance Company
0.03%
Other
14.78%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1017
84.37M
80.60%
-20.51M
2025Q2
1032
95.91M
98.15%
-10.95M
2025Q1
1077
102.36M
104.40%
-6.43M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
10.64M
10.17%
+1.51M
+16.51%
Aug 29, 2025
BlackRock Institutional Trust Company, N.A.
9.84M
9.4%
+937.08K
+10.53%
Jun 30, 2025
D. E. Shaw & Co., L.P.
5.06M
4.83%
+581.27K
+12.98%
Jul 18, 2025
State Street Investment Management (US)
4.70M
4.49%
+626.55K
+15.40%
Jun 30, 2025
Two Sigma Investments, LP
4.15M
3.96%
+3.31M
+397.77%
Jun 30, 2025
Barry (Richard J)
3.21M
3.07%
+32.60K
+1.02%
May 16, 2025
Wellington Management Company, LLP
2.53M
2.42%
-116.16K
-4.39%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.88M
1.79%
+55.08K
+3.02%
Jun 30, 2025
Erste Asset Management GmbH
1.62M
1.55%
+560.35K
+52.81%
Jun 30, 2025
Qube Research & Technologies Ltd
1.60M
1.53%
+1.57M
+4909.63%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
First Trust NYSE Arca Biotechnology Index Fund
3.25%
iShares Neuroscience and Healthcare ETF
1.62%
Invesco S&P SmallCap Health Care ETF
1.21%
Global X Genomics & Biotechnology ETF
1.11%
Virtus LifeSci Biotech Products ETF
0.81%
Invesco S&P SmallCap 600 Pure Growth ETF
0.66%
SPDR S&P Biotech ETF
0.65%
WisdomTree BioRevolution Fund
0.43%
Direxion Daily S&P Biotech Bull 3X Shares
0.4%
VanEck Biotech ETF
0.35%
View more
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.25%
iShares Neuroscience and Healthcare ETF
Proportion1.62%
Invesco S&P SmallCap Health Care ETF
Proportion1.21%
Global X Genomics & Biotechnology ETF
Proportion1.11%
Virtus LifeSci Biotech Products ETF
Proportion0.81%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion0.66%
SPDR S&P Biotech ETF
Proportion0.65%
WisdomTree BioRevolution Fund
Proportion0.43%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.4%
VanEck Biotech ETF
Proportion0.35%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
